{"id":"NCT00910624","sponsor":"Merck Sharp & Dohme LLC","briefTitle":"Boceprevir Treatment in Participants With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin (P05514)","officialTitle":"A Single-Arm Study to Provide Boceprevir Treatment in Subjects With Chronic Hepatitis C Genotype 1 Deemed Nonresponders to Peginterferon/Ribavirin in Previous Schering-Plough Boceprevir Studies","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-06-22","primaryCompletion":"2012-12-07","completion":"2012-12-07","firstPosted":"2009-06-01","resultsPosted":"2013-11-19","lastUpdate":"2021-02-08"},"enrollment":168,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Boceprevir","otherNames":["SCH 503034"]},{"type":"BIOLOGICAL","name":"Peginterferon alfa-2b (SCH 54031)","otherNames":["PegIntron, PEG"]},{"type":"DRUG","name":"Ribavirin (SCH 18908)","otherNames":["Rebetol, RBV"]}],"arms":[{"label":"BOC + PEG/RBV","type":"EXPERIMENTAL"}],"summary":"This is a single-arm, multicenter study of boceprevir (BOC) in combination with peginterferon plus ribavirin (PEG/RBV) in adult chronic hepatitis C (CHC) genotype 1 participants who completed their per-protocol defined treatment and did not achieve sustained viral response (SVR) while in the PEG/RBV control arm(s) of an Schering-Plough Research Institute (SPRI) study of BOC combination therapy. Participants who are able to enroll in this study within 2 weeks after the last dose of PEG/RBV in previous protocol are to receive BOC+ PEG/RBV for up to 44 weeks followed by 24 weeks post-treatment follow-up. Participants who are not able to enroll in this study within 2 weeks after the last dose of PEG/RBV in previous protocol are to receive PEG/RBV for 4 weeks followed by BOC+ PEG/RBV for up to 44 weeks, with 24 weeks post-treatment follow-up.","primaryOutcome":{"measure":"Percentage of Participants With Sustained Virologic Response at Follow-Up Week 24 (SVR24);","timeFrame":"From start of 4-week PEG/RBV lead-in therapy or 44-week BOC/PR treatment through Follow-Up Week (FW) 24 (up to 68 weeks)","effectByArm":[{"arm":"BOC + PEG/RBV: Prior Null Responders","deltaMin":41,"sd":null},{"arm":"BOC + PEG/RBV: Prior Partial Responders","deltaMin":67,"sd":null},{"arm":"BOC + PEG/RBV: Prior Relapsers","deltaMin":96,"sd":null},{"arm":"BOC + PEG/RBV: All","deltaMin":65,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":5,"exclusionCount":1},"locations":{"siteCount":0,"countries":[]},"refs":{"pmids":["24362076"],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":18,"n":168},"commonTop":["Anaemia","Fatigue","Dysgeusia","Nausea","Headache"]}}